tbuckley/cabot-search huggingface dataset:
4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation
Authors: Pavel Osmancik, Dalibor Herman, Petr Neuzil, Pavel Hala, Milos Taborsky, Petr Kala, Martin Poloczek, Josef Stasek, Ludek Haman, Marian Branny, Jan Chovancik, Pavel Cervinka, Jiri Holy, Tomas Kovarnik, David Zemanek, Stepan Havranek, Vlastimil Vancura, Petr Peichl, Petr Tousek, Veronika Lekesova, Jiri Jarkovsky, Martina Novackova, Klara Benesova, Petr Widimsky, Vivek Y. Reddy
Journal: Journal of the American College of Cardiology (2021)
Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)
Authors: Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima
Journal: Blood (2021)
Abstract 13319: Subclinical Atherosclerosis in American Indian Adolescents and Young Adults and the Risk of Fatal and Non-Fatal Cardiovascular Events: The Strong Heart Family Study (SHFS)
Authors: Jessica A Reese, Mary J Roman, Jason Deen, Tauqeer Ali, Shelley Cole, Richard B Devereux, Amanda M Fretts, Barbara Howard, Elisa T Lee, Kimberly Malloy, Parmanand SINGH, Jason G Umans, Ying Zhang
Journal: Circulation (2021)

Introduction: Rates of cardiovascular disease (CVD) among American Indians (AI) have been increasing. Subclinical atherosclerosis is typically detected later in life and may develop into clinical CVD. Although investigators have established the association in older adults, the burden of subclinical atherosclerosis and its relation to CVD risk among AI youth is unclear. Hypothesis: Subclinical atherosclerosis will be prevalent and the risk of CVD will be higher in AI with atherosclerotic plaque in adolescence and early adulthood. Methods: We evaluated AI participants from the SHFS, who were 14-39 years old, CVD free, and had a carotid ultrasound at the baseline examination, 2001-2003 (n=1,376). We used carotid ultrasound to detect baseline atherosclerotic plaque. We identified fatal and/or non-fatal CVD events through the end of 2019 with a median follow-up of 17.8 years. We used shared frailty Cox Proportional Hazards models to assess the association between subclinical atherosclerosis and time to CVD events, while controlling for covariates. Results: Among 1,376 participants, 71 (5.2%) had atherosclerotic plaque at baseline. During follow-up, 120 (8.7%) participants had a fatal or non-fatal CVD event. CVD incidence was higher in participants with baseline plaque (13.51/1,000 person-years) than in those without (4.95/1,000 person-years, p=0.0003, Figure 1). Risk of CVD was higher in participants with baseline plaque compared to those without, while controlling for age and obesity (CVD HR=1.85, 95% CI=1.02-3.37, p=0.0420). Conclusions: AI adolescents and young adults have an unexpectedly high prevalence of atherosclerotic plaque, which is independently associated with incident CVD later in life. Thus, atherosclerosis begins early in life and interventions in adolescents and young adults to slow the progression of disease could prevent or delay CVD events later in life.
Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes
Authors: Tapan M. Kadia, Naveen Pemmaraju, Musa Yilmaz, Naval Daver, Li Li, Mi-Ae Lyu, Meixian Huang, Ke Zeng, Robin Cook, Simrit Parmar, Siddhartha Mukherjee, Tara Sadeghi, Courtney D. DiNardo, Ghayas C. Issa, Elias J. Jabbour, Gautam Borthakur, Nitin Jain, Srdan Verstovsek
Journal: Blood (2021)
Administration of FVIII-Expressing Human Placental Cells to Juvenile Sheep Yields Multi-Organ Engraftment, Therapeutic Plasma FVIII Levels and Alter Immune Signaling Pathways to Evade FVIII Inhibitor Induction
Authors: Brady Trevisan, Martin Rodriguez, Jacqueline Dizon, Sunil George, Jordan E Shields, Shannon Lankford, Rebecca Combs, John Owen, Anthony Atala, Christopher B Doering, H. Trent Spencer, Christopher D Porada, M. Graca Almeida-Porada
Journal: Blood (2021)
Abstract 9997: Sex Differences in Chamber Remodeling Associated with Non-Ischemic Cardiomyopathy and Functional Mitral Regurgitation: A Cardiac Magnetic Resonance Study
Authors: Tom Wang, Nicholas Chan, Duygu Kocyigit, Jennifer Bullen, Wai Hong W Tang, Brian P Griffin, Scott D Flamm, Deborah H Kwon
Journal: Circulation (2021)

Background: Sex differences in the chamber sizes of healthy individuals by echocardiography and magnetic resonance imaging (MRI) are well-established, however chamber remodeling discrepancies in cardiomyopathies and functional mitral regurgitation (FMR) are not well understood. This study compared MRI chamber quantification and remodeling parameters by sex in patients with non-ischemic cardiomyopathy (NICM) and varying degrees of FMR. Methods: We retrospectively studied 633 adult NICM patients undergoing MRI during 2002-2017. Quantitative chamber size, function and left ventricular remodeling parameters by MRI were compared by sex, adjusted for age, hypertension and diabetes, and assessed against FMR severity. Results: Mean age was 52.6 years and 256 (40.4%) patients were women. Significant adjusted women minus men mean differences (95%CI) include left ventricular end-diastolic volume indexed (LVEDVi) -8.5 (-15.1, -1.9)mL/m2 P=0.012, left ventricular mass indexed -11.7 (-15.6, -7.9)g/m2 P&lt;0.001, sphericity ratio -0.08 (-0.13, -0.03) P=0.002, relative wall thickness (RWT) -4.5 (-7.2, -1.8)% P=0.001, right ventricular end-diastolic volume indexed (RVEDVi) -16.0 (-20.3, -11.8) mL/m2 P&lt;0.001, right ventricular ejection fraction +5.2 (+3.2, +7.2)% P&lt;0.001, and right atrial volume indexed (RAVi) -10.5 (-13.6, -7.4) mL/m2 P&lt;0.001, while left ventricular ejection fraction, late gadolinium enhancement score and left atrial volume indexed were similar. With increasing FMR severity, LVEDVi and LAVi had a more prominent increase in women than men, while LVMi, sphericity ratio, RWT, RVEDVi and RAVi were consistently lower for women(Figure). Conclusion: Although women had significantly lower chamber size, RWT and sphericity ratio in NICM than men, their left-sided chamber sizes increased more steeply as FMR increased. These exploratory MRI findings highlight sex differences in chamber remodeling in NICM and responses to greater degree of FMR.
Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses
Authors: Nina Kim, Jonathon Vallejo, Jonathan Herz, Thomas Gwise, R. Angelo de Claro, Marc Theoret, Richard Pazdur, Kelly J. Norsworthy
Journal: Blood (2021)
Donor Socioeconomic Status As a Predictor of Altered Immune Function and Treatment Response Following Hematopoietic Cell Transplantation for Hematologic Malignancy
Authors: Lucie M Turcotte, Tao Wang, Kirsten M Beyer, Steve W Cole, Stephen R. Spellman, Mariam Allbee-Johnson, Eric Williams, Yuhong Zhou, Michael R Verneris, Jennifer M Knight
Journal: Blood (2021)
Abstract 9006: Covid-19 Infection and Incident Myocarditis: A Population-Based Propensity Score-Adjusted Analysis
Authors: Shivani Priyadarshni, Jacques Baillargeon, Jordan Westra, Yong-Fang Kuo, Mukaila Raji
Journal: Circulation (2021)

Introduction: COVID-19-infection caused by Severe Acute Respiratory Syndrome Coronavirus -2—has protean manifestations ranging from asymptomatic infection to multi-organ failure and death. Cardiovascular complications from COVID -19 include myocarditis, acute myocardial infarction (AMI), heart failure (HF). These complications—captured clinically and by tests (troponins, 2-D ECHO, MRI)—can occur either by direct injury to the myo-pericardium or by an inflammatory response and cytokine storm. Population-level data is lacking on the relationship between COVID-19 and onset of Myocarditis, AMI, and HF. Therefore, we examined the incidence and correlations of Myocarditis, AMI, and HF after COVID-19 infection across the United States using a large nationwide database. Hypothesis: Infection with COVID-19 is associated with an increased risk of myocarditis. Methods: We used a retrospective cohort study using de-identified data from 35 health systems across the United States. Cohort groups were created using patients ≥18, who were admitted to hospitals for respiratory illness with COVID in 2020 and respiratory illness without COVID-19 for the years 2020 and 2019. Patients with prior cardiovascular events were excluded from the study. There were 103,187 patients with COVID; 77,242 patients with respiratory illness in 2020, and 114,908 patients with respiratory illness in 2019. The COVID group was matched to each of the respiratory illness groups by propensity score. Three main cardiovascular outcomes were studied: myocarditis, AMI, HF. Results: In the COVID-19 group, 79 patients had new-onset myocarditis compared to 29 patients in the non-COVID-19 control group (Odds ratio [OR] 2.73, CI 95%, 1.78-4.18). In the COVID-19 group, 1512 patients developed HF compared to 2,659 patients in the non-COVID-19 group, (OR 0.49, CI 95%, 0.46-0.52). 1125 patients in COVID-19 group had AMI compared to 1243 patients in non-COVID-19 group (OR 0.87, CI 95 %, 0.80-0.94). Conclusions: COVID-19 patients had 2 to 3 times the odds of incident myocarditis compared to non-COVID controls. Unexpected findings were the lower rates of HF diagnoses in the COVID -19 group, suggesting possible under testing (e.g., 2-D ECHO) and underdiagnosis in isolated COVID patients.
Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers
Authors: Laura K. Schmalbrock, Krischan Braitsch, Paul Jung, Irmgard Bumeder, Philipp Kiewe, Jörg Westermann, Lars Bullinger, Ulrich Keller, Florian Bassermann, Jan Krönke, Kathrin Rieger, Katharina S. Goetze
Journal: Blood (2021)
Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia
Authors: Tamara P. Miller, Nicholas P. DeGroote, Lauren Pommert, Oluwafunbi Awoniyi, Sarah Board, Ngozi Ugboh, Vivek Joshi, Nicholas Ambrosino, Allison Weisnicht, Heidi Hsiao, Melanie Brooke Bernhardt, Eric S Schafer, Maureen M. O'Brien, Sharon M. Castellino, Laura B. Ramsey
Journal: Blood (2021)
Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis
Authors: Nico Gagelmann, Anita Badbaran, Markus Ditschkowski, Victoria Panagiota, Bruno Cassinat, Michael Heuser, Felicitas Thol, Christine Wolschke, Rachel B. Salit, Marie Robin, Dietrich W. Beelen, Bart L. Scott, Nicolaus Kroeger
Journal: Blood (2021)
Burden of influenza disease in children under 2 years of age hospitalized between 2011 and 2020 in France
Authors: Célia Tillard, Emmanuel Chazard, Karine Faure, Stéphanie Bartolo, Alain Martinot, François Dubos
Journal: Journal of Infection (2021)

Although influenza viruses cause significant morbidity and mortality worldwide, the impact of these infections on children in France and in other European countries has not been extensively characterized. The primary objective of the present study was to describe the burden of influenza disease on hospitalized children under 2 years of age in France, using data from the national hospital discharge summary database (Programme de Médicalisation des Systèmes d'Information, PMSI).In a retrospective study of hospital admissions for influenza among children under the age of 2 in France, we extracted and analyzed hospital administrative data from the PMSI database (from January 1, 2011, to December 31, 2020).From 2011 to 2020, 28,507 children under the age of 2 were admitted to hospital with a primary or secondary diagnosis of influenza infection. The hospital admission rate was 205 per 100,000 for children under the age of 2, 276 per 100,000 for children under the age of 12 months, and 135 per 100,000 for children aged between 12 and 23 months. Children under 6 months of age were the most affected (45.4%). An underlying condition was identified for 9.4% of the children, and 2.2% of the children were admitted to the intensive care unit. The death rate was 0.12 per 100,000 for children under 2, 0.11 per 100,000 for children under 12 months, and 0.16 per 100,000 for children aged between 12 and 23 months.In France, the burden of influenza disease is significant in children under the age of 2.
Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial
Authors: Sridhar Chaganti, Shanna Maycock, Graham McIlroy, Waleed A Iqbal, John Mason, Edward Kanfer, Shireen Kassam, Kate Cwynarski, David Wrench, Arvind K. Arumainathan, Christopher P Fox, Rod Johnson, Pam McKay, Shankara Paneesha, Clare J Rowntree, Constantine-George Balotis, Graham P. Collins, Andrew Davies, Josh Wright, Keith Wheatley, Tobias F Menne
Journal: Blood (2021)
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
Authors: Qingda Meng, Shanshan Xie, G Kenneth Gray, Mohammad H Dezfulian, Omar Gandarilla, Weilin Li, Ling Huang, Dipikaa Akshinthala, Elizabeth Ferrer, Catherine Conahan, Sofia Perea Del Pino, Joseph Grossman, Stephen J Elledge, Manuel Hidalgo, Senthil K Muthuswamy
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Tumor-specific cytotoxic T cells and T cell receptors are effective tools for cancer immunotherapy. Most efforts to identify them rely on known antigens or lymphocytes that have infiltrated into the tumor bed. Approaches to empirically identify tumor-targeting T cells and T cell receptors by exploiting all antigens expressed on tumor cell surfaces are not well developed for most carcinomas, including pancreatic cancer. Methods Autologous tumor organoids were stimulated with T cells from the patients’ peripheral blood for 2 weeks to generate the organoid-primed T (opT) cells. opT cell phenotype was analyzed by monitoring changes in the expression levels of 28 cell surface and checkpoint proteins. Expression of ligands of the immune checkpoints was investigated by immunohistochemistry staining. T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) and assayed by flow cytometry to monitor tumor-induced T cell proliferation changes. opT cell-mediated killing of three-dimensional organoids was measured using an M30 ELISA kit. T cell receptors (TCRs) were identified by deep sequencing of gDNA isolated from T cells, and the TCR specificity was confirmed by transferring TCRs to the T cell line SKW-3 or donor T cells. Results The co-culture was effective in the generation of CD8 + or CD4+opT cells. The opT cells killed autologous tumors in a granzyme B or Fas-Fas ligand-dependent manner and expressed markers of tissue-resident memory phenotype. Each patient-derived opT cell culture displayed a unique complement of checkpoint proteins. Interestingly, only NKG2A blockade showed a potent increase in the interferon-γ production compared with blocking programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) or TIM3 or TIGIT or LAG3. Importantly, TCR sequencing demonstrated a dramatic clonal expansion of T cells with a restricted subset of TCRs. Cloning and transferring the TCRs to heterologous T cells was sufficient to confer tumor cell recognition and cytotoxic properties in a patient-specific manner. Conclusion We report a platform for expanding tumor-targeting T cells from the peripheral blood of patients with pancreatic cancer. We identify the NKG2A-HLA-E axis as a potentially important checkpoint for CD8 +T cells for pancreatic cancer. Lastly, we demonstrate empirical identification of tumor-targeting TCRs that can be used for TCR-therapeutics.
Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials
Authors: Reshma Ramachandran, Joseph S. Ross, Jennifer E. Miller
Journal: JAMA Network Open (2021)

avoid exploitation.These wealth-based access inequities among countries hosting trials parallel general disparities in COVID-19 vaccine access, as high-income countries have successfully procured and administered doses ahead of low-and middle-income countries. 5,6udy limitations include inability to determine the number of enrolled trial participants per country, which was not systematically reported, and the impact of manufacturing errors and safety concerns on dosage delivery, particularly affecting AstraZeneca and Janssen.Further, we focused on vaccination rates with vaccines tested in clinical trials hosted by each country, not overall vaccination rates with any authorized COVID-19 vaccine.
Abstract 10642: A New Echocardiographic Parameter is a Strong Predictor of New-onset Atrial Fibrillation: Results From a Prospective Study in 566 Elderly Subjects Followed-up for 4 Years
Authors: Takasi Yosizane, Michael R Zile, Masanori Kawasaki, Ryuhei Tanaka, Koji Ono, Takatomo Watanabe, Reiko Matsuoka, Shintaro Abe, Tai Kojima, Shunichiro Warita, Makoto Iwama, Takeshi Hirose, Masazumi Arai, Mami Iida, Toshiyuki Noda, Sachiro Watanabe, Shinya Minatoguchi
Journal: Circulation (2013)

Background: The incidence of new-onset atrial fibrillation (AF) is increasing with age. However, the specific causes of new-onset AF are not well known. We reported that pulmonary capillary wedge p...
Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty‐Eight–Joint Disease Activity Score, C‐Reactive Protein Level, and Patient Global Assessment
Authors: David T. Felson, Diane Lacaille, Michael P. LaValley, Daniel Aletaha
Journal: Arthritis & Rheumatology (2021)

### Editor's note

The Editors of the 5 journals of the American College of Rheumatology and European Alliance of Associations for Rheumatology have been reminded by this editorial that ACR and EULAR have jointly agreed on various classification criteria, definitions, recommendations, or points to consider, which do not always find reflection in manuscripts submitted to the journals. Consequently, in the future, the Editors will enforce the use of the products obtained in the course of joint ACR/EULAR or EULAR/ACR activities in all respective papers. For rheumatoid arthritis this would mean use of the ACR/EULAR or EULAR/ACR classification criteria, remission definitions, recommendations on what to report in clinical trials, and others, as pertinent. The same applies to other diseases. There are valid and important reasons that these activities have been undertaken by ACR and EULAR, and therefore, the conclusions of the various task forces, which have been endorsed by ACR and EULAR, should be respected by investigators and study administrators. This does not mean other methods could not be used in a study, but at the least, the reports should address the methods agreed upon by the 2 organizations. Maintaining uniformity across major publications regarding rheumatoid arthritis remission or other definitions not only allows for more appropriate comparison across analyses, but also enhances readers' ability to interpret results. Author instructions across the 5 journals will more strongly reflect this requirement.

Over the last 30 years, treatment for RA has improved dramatically. By the early 2000s, disease remission had become a realistic goal, although definitions of remission varied widely, making it difficult to compare treatment strategies and gauge how often remission occurred. In 2009, the ACR and the EULAR created a joint committee whose charge was to recommend a definition of remission. Members of the committee suggested a large number of candidate definitions and using …
25 Potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer
Authors: Leeseul Kim, Young Kwang Chae, Dong-Uk Lee
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Predicting immune-related adverse events (irAEs) in early stage is being emphasized even more. Host response to disease is reflected in serum proteome level and that allows serum proteome level as a new marker to explore response to immunotherapy. With the help of a serum-based proteomics test, Primary Immune Response (PIR), we are accessing the correlations between developing irAEs and immunotherapy in non-small cell lung cancer (NSCLC) patients. Methods Data of 48 consented NSCLC patients with baseline PIR test done within one week prior to the start of immunotherapy were collected. Samples were grouped into either sensitive or intermediate/resistant (not sensitive) by PIR classification. We analyzed the durations from the immunotherapy initiation to the first episode of irAE. IrAEs were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Results Among the 48 NSCLC patients, 19 patients (39%) experienced one or more irAEs with the majority classified as either grade 1 (n=7, 36%) or grade 2 (n=10, 52%). PIR-sensitive group showed no difference in irAE free period compared to PIR-not sensitive (p=0.92, HR=0.95, 95% CI=00.3212 to 2.834). The median ‘Time to first irAE’ were undefined and 24 in PIR-sensitive and PIR-not sensitive, respectively. Conclusions Our results demonstrated PIR-sensitive patients are not likely to tolerate immunotherapy longer without developing irAEs.
A hypoxia-responsive supramolecular formulation for imaging-guided photothermal therapy
Authors: Tian-Xing Zhang, Xiaoxue Hou, Yong Kong, Fan Yang, Yu-Xin Yue, Muhammad Raza Shah, Hua-Bin Li, Fan Huang, Jianfeng Liu, Dong-Sheng Guo
Journal: Theranostics (2021)

Photothermal agents (PTAs) based on organic small-molecule dyes emerge as promising theranostic strategy in imaging and photothermal therapy (PTT). However, hydrophobicity, photodegradation, and low signal-to-noise ratio impede their transformation from bench to bedside. In this study, a novel supramolecular PTT formulation by a stimuli-responsive macrocyclic host is prepared to overcome these obstacles of organic small-molecule PTAs. Methods: Sulfonated azocalix[4]arene (SAC4A) was synthesized as a hypoxia-responsive macrocyclic host. Taking IR780 as an example, the supramolecular nanoformulation IR780@SAC4A was constructed by grinding method, and its solubility, photostability, and photothermal conversion were evaluated. The hypoxia tumor-selective imaging and supramolecular PTT of IR780@SAC4A were further evaluated in vitro and in vivo. Results: IR780@SAC4A is capable of enhancing the solubility, photostability, and photothermal conversion of IR780 significantly, which achieve this supramolecular formulation with good imaging-guided PTT efficacy in vitro and in vivo. Conclusions: This study demonstrates that the supramolecular PTT strategy is a promising cancer theranostic method. Moreover, this supramolecular approach is applicative to construct kinds of supramolecular PTAs, opening a general avenue for extending smart PTT formulations.
A Novel <i>RPS19</i>-Edited Hematopoietic Stem Cell Model of Diamond-Blackfan Anemia for Development of Lentiviral Vector Gene Therapy
Authors: Senthil Velan Bhoopalan, Jonathan Yen, Thiyagaraj Mayuranathan, Yu Yao, Kalin Mayberry, Sheng Zhou, Robert Throm, Marcin W. Wlodarski, Mitchell J. Weiss
Journal: Blood (2021)
Antibiotic Stewardship in Patients after Cellular Therapy with Febrile Neutropenia- a Single Center Prospective Unblinded Randomized Trial
Authors: Ron Ram, Odelia Amit, Amos Adler, Yael Bar-On, Ofrat Beyar-Katz, Irit Avivi, David Shasha, Ronen Ben-Ami
Journal: Blood (2021)